Abstract
Circumstantial evidence has been provided of a role of the plasminogen/plasmin system in a variety of biological phenomena, including thrombolysis, vascular stenosis, reproduction, embryogenesis, cell invasion, angiogenesis, brain function and chronic lung or kidney inflammatory disorders. Inhibition of the system occurs either at the levels of plasminogen activator, regulated by specific plasminogen activator inhibitors (PAIs) or at the levels of plasmin, mainly regulated by α2-antiplasmin (α2-AP). α2-AP is a specific plasmin inhibitor. We investigated the role of α2-AP on arterial or venous thrombus formation using mice deficient α2-AP and the interactions among lack of α2-AP, antiplatelet, anticoagulant and thrombolytic compounds were evaluated using murine thrombus model. These results clearly indicate that α2-AP plays a different role in acute arterial thrombosis or venous thrombosis. Additionally, lack of α2-AP significantly affected anti-coagulant and thrombolytic action, but not anti-platelet compounds, on the development of thrombus formation in vivo. Recent findings reported that plasmin cleaves vascular endothelial growth factor (VEGF) in extracellular matrix. Our findings newly indicate that lack of α2-AP enhances the secretion of VEGF in acute myocardial infarction and over secretion of VEGF promotes heart failure by pulmonary edema. Moreover, regulation of VEGF by α2-AP significantly affected reendothelialization after vascular injury. These findings indicate a potential new aspect in this field and could be a useful report for the development of novel antithrombotic compounds.
Keywords: vascular diseases, thrombolytic, VENOUS THROMBOSIS, vascular endothelial growth factor (VEGF), plasminogen activator inhibitors (PAIs)
Current Pharmaceutical Design
Title: α2-Antiplasmin on Cardiovascular Diseases
Volume: 12 Issue: 7
Author(s): Hiroyuki Matsuno
Affiliation:
Keywords: vascular diseases, thrombolytic, VENOUS THROMBOSIS, vascular endothelial growth factor (VEGF), plasminogen activator inhibitors (PAIs)
Abstract: Circumstantial evidence has been provided of a role of the plasminogen/plasmin system in a variety of biological phenomena, including thrombolysis, vascular stenosis, reproduction, embryogenesis, cell invasion, angiogenesis, brain function and chronic lung or kidney inflammatory disorders. Inhibition of the system occurs either at the levels of plasminogen activator, regulated by specific plasminogen activator inhibitors (PAIs) or at the levels of plasmin, mainly regulated by α2-antiplasmin (α2-AP). α2-AP is a specific plasmin inhibitor. We investigated the role of α2-AP on arterial or venous thrombus formation using mice deficient α2-AP and the interactions among lack of α2-AP, antiplatelet, anticoagulant and thrombolytic compounds were evaluated using murine thrombus model. These results clearly indicate that α2-AP plays a different role in acute arterial thrombosis or venous thrombosis. Additionally, lack of α2-AP significantly affected anti-coagulant and thrombolytic action, but not anti-platelet compounds, on the development of thrombus formation in vivo. Recent findings reported that plasmin cleaves vascular endothelial growth factor (VEGF) in extracellular matrix. Our findings newly indicate that lack of α2-AP enhances the secretion of VEGF in acute myocardial infarction and over secretion of VEGF promotes heart failure by pulmonary edema. Moreover, regulation of VEGF by α2-AP significantly affected reendothelialization after vascular injury. These findings indicate a potential new aspect in this field and could be a useful report for the development of novel antithrombotic compounds.
Export Options
About this article
Cite this article as:
Matsuno Hiroyuki, α2-Antiplasmin on Cardiovascular Diseases, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056038
DOI https://dx.doi.org/10.2174/138161206776056038 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcineurin Inhibition and Development: Insights from Research Models
Current Enzyme Inhibition Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments
Current Medicinal Chemistry Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Letters in Drug Design & Discovery Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Current Pharmaceutical Design Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Role of Solid Lipid Nanoparticles for the Delivery of Lipophilic Drugs and Herbal Medicines in the Treatment of Pulmonary Hypertension
Pharmaceutical Nanotechnology Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Oxygen Free Radicals and Their Biomedical Implications: A Mini Review
Mini-Reviews in Organic Chemistry Posttransplant Diabetes Mellitus (PTDM) Following Solid Organ Transplantation - Systematic Analysis of Prevalence and Total Mortality and Meta-Analysis of Randomized Interventional Studies Aimed at Lowering Blood Glucose
Current Diabetes Reviews Status Epilepticus: An Overview
Current Drug Metabolism Study on the Effect of HPMC on Compression Coated Floating Pulsatile Delivery of Bisoprolol
Current Drug Therapy Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Summaries of Selected Presentations from the 2012 Annual Meeting of the American Society for Adolescent Psychiatry
Adolescent Psychiatry Unwinding Link between Coronavirus and Diabetes Patient
Endocrine, Metabolic & Immune Disorders - Drug Targets